Functional protease profiling with reporter peptides in serum specimens of colorectal cancer patients: Demonstration of its routine diagnostic applicability

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Findeisen, Peter ^a   Costina, Victor ^a   Yepes, Diego ^a   Hofheinz, Ralf ^a   Neumaier, Michael ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cancer procoagulant diagnosis; Colorectal cancer; Functional protease profiling; Mass spectrometry; Reporter peptide; Serum

Indexed keywords

AMINO ACID; CANCER PROCOAGULANT; CYSTEINE PROTEINASE; PROTEINASE; TRYPTOPHYLLYSYLPROLYLTYROSYLASPARTYLALANYLALANYLASPARTIC ACID; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CALIBRATION; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME SUBSTRATE; EX VIVO STUDY; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEOMICS; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; REPORTER GENE; REPRODUCIBILITY; ROOM TEMPERATURE; TUMOR GROWTH;

AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PEPTIDE HYDROLASES; PEPTIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 84861932206     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-56     Document Type: Article

References (36)

1. Proteases: multifunctional enzymes in life and disease. Lopez-Otin C, Bond JS, J Biol Chem 2008 283 45 30433 30437 10.1074/jbc.R800035200 18650443
2. Local proteolytic activity in tumor cell invasion and metastasis. Ludwig T, Bioessays 2005 27 11 1181 1191 10.1002/bies.20306 16237672 (Pubitemid 43076144)
3. Up-regulation of gelatinases in the colorectal adenoma-carcinoma sequence. Gimeno-Garcia AZ, Santana-Rodriguez A, Jimenez A, Parra-Blanco A, Nicolas-Perez D, Paz-Cabrera C, Diaz-Gonzalez F, Medina C, Diaz-Flores L, Quintero E, Eur J Cancer 2006 42 18 3246 3252 10.1016/j.ejca.2006.06.025 16973348 (Pubitemid 44854506)
4. New functions for the matrix metalloproteinases in cancer progression. Egeblad M, Werb Z, Nature reviews 2002 2 3 161 174 10.1038/nrc745 11990853 (Pubitemid 37328786)
5. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Garfall AL, Berman T, Joyce JA, Genes Dev 2010 24 3 241 255 10.1101/gad.1874010 20080943
6. Spiking of serum specimens with exogenous reporter peptides for mass spectrometry based protease profiling as diagnostic tool. Findeisen P, Peccerella T, Post S, Wenz F, Neumaier M, Rapid Commun Mass Spectrom 2008 22 8 1223 1229 10.1002/rcm.3496 18348224 (Pubitemid 351600772)
7. Monitoring peptidase activities in complex proteomes by MALDI-TOF mass spectrometry. Villanueva J, Nazarian A, Lawlor K, Tempst P, Nat Protoc 2009 4 8 1167 1183 10.1038/nprot.2009.88 19617888
8. Endoprotease profiling with double-tagged peptide substrates: a new diagnostic approach in oncology. Peccerella T, Lukan N, Hofheinz R, Schadendorf D, Kostrezewa M, Neumaier M, Findeisen P, Clin Chem 2010 56 2 272 280 10.1373/clinchem.2009.133462 20110451
9. Differential expression of protease activity in serum samples of prostate carcinoma patients with metastases. Dekker LJ, Burgers PC, Charif H, van Rijswijk AL, Titulaer MK, Jenster G, Bischoff R, Bangma CH, Luider TM, Proteomics 2010 10 12 2348 2358 10.1002/pmic.200900682 20394078
10. Circulating MMP2 and MMP9 in breast cancer - potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Somiari SB, Somiari RI, Heckman CM, Olsen CH, Jordan RM, Russell SJ, Shriver CD, Int J Cancer 2006 119 6 1403 1411 10.1002/ijc.21989 16615109 (Pubitemid 44258818)
11. Addition of exogenous reporter peptides to serum samples before mass spectrometry-based protease profiling provides advantages over profiling of endogenous peptides. Findeisen P, Post S, Wenz F, Neumaier M, Clin Chem 2007 53 10 1864 1866 10.1373/clinchem.2006.083030 17885140 (Pubitemid 47509684)
12. Test systems with synthetic peptide substrates in haemostaseology. Witt I, Eur J Clin Chem Clin Biochem 1991 29 6 355 374 1912084
13. Investigating the quantitative nature of MALDI-TOF MS. Szajli E, Feher T, Medzihradszky KF, Mol Cell Proteomics 2008 7 12 2410 2418 10.1074/mcp.M800108- MCP200 18653768
14. Intrinsic peptidase activity causes a sequential multi-step reaction (SMSR) in digestion of human plasma peptides. Yi J, Liu Z, Craft D, OMullan P, Ju G, Gelfand CA, J Proteome Res 2008 7 12 5112 5118 10.1021/pr800396c 19367699
15. MEROPS: the peptidase database. Rawlings ND, Morton FR, Kok CY, Kong J, Barrett AJ, Nucleic Acids Res 2008 36 Database issue 320 D325 17991683
16. Systemic inflammation as a confounding factor in cancer biomarker discovery and validation. Chechlinska M, Kowalewska M, Nowak R, Nature reviews 2010 10 1 2 3 20050335
17. Statistical methods for assessing agreement between two methods of clinical measurement. Bland JM, Altman DG, Lancet 1986 1 8476 307 310 2868172 (Pubitemid 16134762)
18. Biochemistry of cancer procoagulant. Mielicki WP, Haemostasis 2001 31 Suppl 1 8 10 11990487
19. Quality assessment of quantitative analytical results in laboratory medicine by root mean square of measurement deviation. McDonald R, J Lab Med 2006 30 3 111 117
20. Functional protease profiling for diagnosis of malignant disease. Findeisen P, Neumaier M, Proteomics Clin Appl 2012 6 1-2 60 78 22213637
21. Analysis of serum cancer procoagulant activity and its possible use as a tumor marker. Gordon SG, Benson B, Thromb Res 1989 56 3 431 440 10.1016/0049-3848(89)90256-9 2617480 (Pubitemid 20003597)
22. Procoagulant factors in patients with cancer. Molnar S, Guglielmone H, Lavarda M, Rizzi ML, Jarchum G, Hematology (Amsterdam, Netherlands) 2007 12 6 555 559 (Pubitemid 350048067)
23. A sequence-specific exopeptidase activity test (SSEAT) for functional biomarker discovery. Villanueva J, Nazarian A, Lawlor K, Yi SS, Robbins RJ, Tempst P, Mol Cell Proteomics 2008 7 3 509 518 17986438 (Pubitemid 351472461)
24. The absolute quantification of eight inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4)-derived peptides in serum from breast cancer patients. van den Broek I, Sparidans RW, van Winden AW, Gast MC, van Dulken EJ, Schellens JH, Beijnen JH, Proteomics Clin Appl 2010 4 12 931 939 10.1002/prca.201000035 21137033
25. Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up. Murao N, Ishigai M, Yasuno H, Shimonaka Y, Aso Y, Rapid Commun Mass Spectrom 2007 21 24 4033 4038 10.1002/rcm.3319 18000836
26. Approved IFCC reference method for the measurement of HbA1c in human blood. Jeppsson JO, Kobold U, Barr J, Finke A, Hoelzel W, Hoshino T, Miedema K, Mosca A, Mauri P, Paroni R, et al. Clin Chem Lab Med 2002 40 1 78 89 11916276 (Pubitemid 34196455)
27. Quantification of intermediate-abundance proteins in serum by multiple reaction monitoring mass spectrometry in a single-quadrupole ion trap. Lin S, Shaler TA, Becker CH, Anal Chem 2006 78 16 5762 5767 10.1021/ac060613f 16906721 (Pubitemid 44265037)
28. An integrated LC-ESI-MS platform for quantitation of serum peptide ladders. Application for colon carcinoma study. Bakun M, Karczmarski J, Poznanski J, Rubel T, Rozga M, Malinowska A, Sands D, Hennig E, Oledzki J, Ostrowski J, et al. Proteomics Clin Appl 2009 3 8 932 946 10.1002/prca.200800111 21136997
29. Peptidomics for cancer diagnosis: present and future. Diamandis E, J Proteome Res 2006 5 9 2079 2082 10.1021/pr060225u 16944917 (Pubitemid 44330798)
30. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Falanga A, Gordon SG, Biochemistry 1985 24 20 5558 5567 10.1021/bi00341a041 3935163 (Pubitemid 16228838)
31. Thrombin induces broad spectrum proteolysis in human serum samples. OMullan P, Craft D, Yi J, Gelfand CA, Clin Chem Lab Med 2009 47 6 685 693 19099528
32. Proteomic analysis of the coagulation reaction in plasma and whole blood using PROTOMAP. Niessen S, Hoover H, Gale AJ, Proteomics 2011 11 12 2377 2388 10.1002/pmic.201000674 21584940
33. Sampling the N-terminal proteome of human blood. Wildes D, Wells JA, Proc Natl Acad Sci U S A 2010 107 10 4561 4566 10.1073/pnas.0914495107 20173099
34. Characterizing human colorectal carcinomas by proteolytic profile. Murnane MJ, Shuja S, Del Re E, Cai J, Iacobuzio-Donahue C, Klepeis V, In vivo (Athens, Greece) 1997 11 3 209 216 (Pubitemid 27348105)
35. Functional phenotyping of human plasma using a 361-fluorogenic substrate biosensing microarray. Gosalia DN, Denney WS, Salisbury CM, Ellman JA, Diamond SL, Biotechnol Bioeng 2006 94 6 1099 1110 10.1002/bit.20927 16575920 (Pubitemid 44221055)
36. Robust substrate profiling method reveals striking differences in specificities of serum and lung fluid proteases. Watson DS, Jambunathan K, Askew DS, Kodukula K, Galande AK, Biotechniques 2011 51 2 95 104 21806553